Indication · GI, Urology & Nephrology
Inflammatory bowel disease
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
49
Cleared or approved since 2000
PMA and De Novo
6
Higher-risk or first-of-kind devices
Breakthrough devices
0
Authorized through June 30, 2026
Recruiting device trials
31
233 device trials in all
Devices
0 devices via PMA. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
No devices on this pathway.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- NaviCam Patency Capsule to Verify Gastrointestinal PatencyNot yet recruiting
AnX Robotica Corp.Not on our public-company list
NCT07649720 · 25 participants (planned) · Start Feb 15, 2027 · Primary completion Sep 30, 2027
Device: NaviCam Patency Capsule · For: Intestinal Stricture; Crohn Disease; NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy and 1 more
Sites: Downers Grove, Illinois
232 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- System, Imaging, Gastrointestinal, Wireless, Capsule (NEZ)24
- Calprotectin, Fecal (NXO)11
- Antibodies, Saccharomyces Cerevisiae (S.Cerevisiae) (NBT)6
- Lactoferrin, Antigen, Antiserum, Control (DEG)4
- Antibodies, Outer-Membrane Proteins (OKM)1
- Anal Fistula Closure Device (QML)1
- Infliximab Test System (QXT)1
- Adalimumab Assay (QYD)1
Research
- Device studies on Crohn disease across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.